Diurnal Group (LON:DNL) announced its quarterly earnings data on Monday. The company reported GBX (12.70) (($0.18)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

Shares of Diurnal Group (LON DNL) traded down GBX 15 ($0.21) on Wednesday, hitting GBX 199 ($2.75). 11,715 shares of the stock traded hands, compared to its average volume of 5,226. The firm has a market cap of $185.23 and a PE ratio of -995.00. Diurnal Group has a 12 month low of GBX 118 ($1.63) and a 12 month high of GBX 215.80 ($2.98).

How to Become a New Pot Stock Millionaire

Separately, Numis Securities reaffirmed a “buy” rating and issued a GBX 185 ($2.56) price objective on shares of Diurnal Group in a research note on Monday, December 18th.

In other Diurnal Group news, insider John Goddard acquired 10,791 shares of the stock in a transaction dated Friday, January 5th. The shares were bought at an average price of GBX 540 ($7.46) per share, with a total value of £58,271.40 ($80,507.60).

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/03/14/diurnal-group-dnl-posts-quarterly-earnings-results.html.

Diurnal Group Company Profile

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.